News
Tolebrutinib reduces disability progression in nonrelapsing secondary progressive multiple sclerosis
In this randomized controlled trial of patients with nonrelapsing secondary progressive multiple sclerosis (SPMS), oral ...
EBV is one of the most common viruses in the world. Over 90% of people get it at some point in their lives. Most people catch ...
Medindia on MSN8d
World Multiple Sclerosis Day: Voices of Strength, Stories of HopeMultiple Sclerosis affects millions worldwide with diverse symptoms; early diagnosis, multidisciplinary care, and awareness ...
Fenebrutinib helped patients with relapsing forms of MS remain nearly free of relapses and disability progression up to two years, data show.
NEW YORK, May 30, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentations of data highlighting BRIUMVI® (ublituximab-xiiy) in patients with relapsing forms of ...
Medical pros revisit the 150-year history of coffee enemas to weigh their potential benefits and hidden dangers.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback